Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIV-1 reverse transcriptase is a multifunctional enzyme essential for HIV replication, possessing both RNA-dependent and DNA-dependent DNA polymerase activities, as well as intrinsic ribonuclease H activity. During the HIV life cycle, this enzyme converts viral single-stranded RNA into double-stranded DNA, enabling integration into the host genome and continued viral propagation. Its central function has made it a primary target for antiretroviral drug development; both nucleoside/nucleotide analogs (NRTIs) and non-nucleoside inhibitors (NNRTIs) inhibit reverse transcriptase, forming the backbone of standard HIV treatment regimens. Drug resistance and toxicity remain clinically important challenges for therapies targeting this enzyme.
Nucleoside/nucleotide reverse transcriptase inhibitors: Incorporated into viral DNA by HIV-1 reverse transcriptase, causing premature DNA chain termination, halting viral replication. Non-nucleoside reverse transcriptase inhibitors: Bind non-competitively to reverse transcriptase at an allosteric site, inducing conformational changes that inhibit enzyme function.
13 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Reverse transcriptase (specifically, HIV-1 reverse transcriptase) (RT).